Sign up
Pharma Capital

Neuren Pharmaceuticals gets green light for a patent in the U.S.

The method has demonstrated efficacy in pre-clinical models of Parkinson’s disease and stroke.
This patent will supplement other patents in the U.S., Europe and Japan

Neuren Pharmaceuticals Ltd (ASX:NEU) has been issued a Notice of Allowance for a new patent for its NNZ-2591 in the U.S., valid up to 2034.

The new patent concerns a method for treating autism spectrum disorder and neurodevelopmental disorders using a neurotrophic peptide (NNZ-2591).

This patent will supplement composition of matter patents in the U.S., Europe and Japan which have been granted until 2024, with the potential to extend expiry to 2029.

NNZ-2591 is a synthetic analog of the neurotrophic peptide cyclic glycine proline (cGP), which occurs naturally in the brain.

It has demonstrated efficacy in pre-clinical models of Parkinson’s disease, stroke, traumatic brain injury, peripheral neuropathy, Fragile X syndrome, memory impairment and multiple sclerosis.

READ: Neuren Pharmaceuticals bags $11.5M to progress Rett syndrome trials

Furthermore, Neuren has confirmed that validation of the recently granted patent concerning the use of its lead molecule trofinetide to treat autism spectrum disorders has now been completed in Europe.

This, along with the U.S patent will strengthen the commercial exclusivity for both trofinetide and NNZ-2591, through a combination of composition of matter patents, method patents and orphan drug exclusivity periods.

Register here to be notified of future NEU Company articles
View full NEU profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.